𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Quality of life in early Parkinson's disease: Impact of dyskinesias and motor fluctuations

✍ Scribed by Connie Marras; Anthony Lang; Murray Krahn; George Tomlinson; Gary Naglie


Publisher
John Wiley and Sons
Year
2004
Tongue
English
Weight
80 KB
Volume
19
Category
Article
ISSN
0885-3185

No coin nor oath required. For personal study only.

✦ Synopsis


Abstract

The impact of dyskinesias and motor fluctuations on quality of life (QOL) at various stages in the course of Parkinson's disease (PD) is not well understood. In 301 subjects with early PD enrolled in a clinical trial (CALM‐PD), we quantified the impact of motor complications on QOL and investigated how this changes over time. We also compared QOL related to demographic and treatment characteristics. The presence of dyskinesias was associated with visual analogue scale (VAS) scores 3.0 of 100 points higher (better) than those without dyskinesias in years 1 to 2, even when adjusting for Unified Parkinson's Disease Rating Scale (UPDRS) motor scores. The positive association between dyskinesias and QOL scores was more marked in older patients. In years 3 to 4, dyskinesias no longer had a significant relationship with QOL. Younger subjects had higher VAS scores. Gender, motor fluctuations, and treatment regimen had no significant association with QOL, although a trend was found toward a small negative effect of motor fluctuations on QOL. We conclude that motor complications that occur within the first 4 years of treatment of PD do not have a significant negative effect on quality of life as measured by a visual analogue scale for most patients. Β© 2003 Movement Disorder Society


πŸ“œ SIMILAR VOLUMES


Motor fluctuations and dyskinesias in Pa
✍ Joseph Jankovic πŸ“‚ Article πŸ“… 2005 πŸ› John Wiley and Sons 🌐 English βš– 93 KB

Fluctuations in the symptoms of Parkinson's disease (PD), such as wearing-off and on-off effects, and dyskinesias are related to a variety of factors, including duration and dosage of levodopa, age at onset, stress, sleep, food intake, and other pharmacokinetic and pharmacodynamic mechanisms. The ma

Pathophysiology of motor fluctuations in
✍ Katherine Widnell πŸ“‚ Article πŸ“… 2005 πŸ› John Wiley and Sons 🌐 English βš– 123 KB

Loss of dopamine neurons in Parkinson's disease (PD) initiates a complex stream of effects that results in the development of tremor, bradykinesia, and rigidity. While levodopa remains the most effective drug for the symptomatic treatment of PD, its chronic administration is associated with the deve

Impact of the motor complications of Par
✍ StΓ©phane Chapuis; Lemlih Ouchchane; Olivier Metz; Laurent Gerbaud; Franck Durif πŸ“‚ Article πŸ“… 2004 πŸ› John Wiley and Sons 🌐 English βš– 86 KB πŸ‘ 1 views

## Abstract The impact of motor complications of Parkinson's disease (PD), especially levodopa‐induced dyskinesias, on quality of life (QL) was studied in 143 patients with PD. All were evaluated on the Hoehn and Yahr (H&Y) scale, and the Motor part of the Unified Parkinson's Disease Rating Scale (

Distribution of motor impairment influen
✍ Kim C. Stewart; Hubert H. Fernandez; Michael S. Okun; Charles E. Jacobson; Chris πŸ“‚ Article πŸ“… 2008 πŸ› John Wiley and Sons 🌐 English βš– 418 KB πŸ‘ 1 views

## Abstract We evaluated the relationship between upper extremity (UE) and lower extremity (LE) motor impairments in Parkinson's disease (PD) to overall disability and quality of life (QoL) measures. A total of 639 patients who were diagnosed with idiopathic PD were administered the Unified Parkins

Onset and spread of dyskinesias and moto
✍ Giovanni Fabbrini; Giovanni Defazio; Carlo Colosimo; Antonio Suppa; Maria Bloise πŸ“‚ Article πŸ“… 2009 πŸ› John Wiley and Sons 🌐 English βš– 68 KB

## Abstract We retrospectively investigated in consecutive Parkinson's disease (PD) outpatients the relationship between the body region in which LID first appeared and the body region where Parkinsonian motor symptoms started. We also studied the spread of LID and motor symptoms to other body part

Rasagiline improves quality of life in p
✍ Kevin M. Biglan; Steven Schwid; Shirley Eberly; Karen Blindauer; Stanley Fahn; T πŸ“‚ Article πŸ“… 2006 πŸ› John Wiley and Sons 🌐 English βš– 164 KB πŸ‘ 1 views

The objective of this study was to determine the effects of rasagiline as monotherapy on quality of life (QOL) in patients with early Parkinson's disease (PD). Rasagiline, a potent, second-generation, irreversible, selective monoamine oxidase B inhibitor improves PD symptoms in patients with early P